GH Research shares surge as depression therapy shows strong trial results

Full story: https://grafa.com/news/health-gh-research-shares-surge-as-depression-therapy-shows-strong-trial-results-364573

Shares of GH Research (NASDAQ:GHRS) skyrocketed 90% to $20.14 in premarket trading after the drug developer announced that its experimental therapy for treatment-resistant depression met its primary goal in a mid-stage clinical trial.

The company reported that its therapy, GH001, significantly reduced the severity of depression as measured on a widely used clinical scale.

Data from the trial showed that 57.5% of patients receiving GH001 experienced a reduction in disease severity within just eight days.

In addition to hitting its main target, GH001 also met all secondary goals of the study, further strengthening its potential as a breakthrough treatment for patients who do not respond to conventional therapies.

Meanwhile, GH Research has seen strong momentum in its stock performance, with shares rising 20.7% in 2024.

The latest trial success has fueled optimism among investors and the medical community, as the company advances GH001 toward further clinical development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

2

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":399633295237776,"tweetId":"399633295237776","gmtCreate":1738592211503,"gmtModify":1738593787838,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":214,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/671f7ba40c50950462508a4cd45dd1cb"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/671f7ba40c50950462508a4cd45dd1cb"}],"title":"GH Research shares surge as depression therapy shows strong trial results","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/671f7ba40c50950462508a4cd45dd1cb\"></p>\n<p>Full story: <a href=\"https://grafa.com/news/health-gh-research-shares-surge-as-depression-therapy-shows-strong-trial-results-364573?utm_source=ttmfinancial&amp;utm_medium=social&amp;utm_campaign=364573&amp;referralcode=A314DFDBE96C354756A893C6E3E02493\">https://grafa.com/news/health-gh-research-shares-surge-as-depression-therapy-shows-strong-trial-results-364573</a></p>\n<p><a href=\"https://grafa.com/learn/shares-55513\">Shares</a> of <a href=\"https://grafa.com/company/gh-research-plc-13111\">GH Research </a><a href=\"https://grafa.com/asset/gh-research-plc-13111-ghrs.nasdaq\">(NASDAQ:GHRS)</a> skyrocketed 90% to $20.14 in premarket trading after the drug developer announced that its experimental therapy for treatment-resistant depression met its primary goal in a mid-stage clinical trial.</p>\n<p>The company reported that its therapy, GH001, significantly reduced the severity of depression as measured on a widely used clinical scale.</p>\n<p>Data from the trial showed that 57.5% of patients receiving GH001 experienced a reduction in disease severity within just eight days.</p>\n<p>In addition to hitting its main target, GH001 also met all secondary goals of the study, further strengthening its potential as a breakthrough treatment for patients who do not respond to conventional therapies.</p>\n<p>Meanwhile, <a href=\"https://grafa.com/company/gh-research-plc-13111\">GH Research </a>has seen strong momentum in its stock performance, with shares rising 20.7% in 2024.</p>\n<p>The latest trial success has fueled optimism among investors and the medical community, as the company advances GH001 toward further clinical development.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/671f7ba40c50950462508a4cd45dd1cb\"></p>\n<p>Full story: <a href=\"https://grafa.com/news/health-gh-research-shares-surge-as-depression-therapy-shows-strong-trial-results-364573?utm_source=ttmfinancial&amp;utm_medium=social&amp;utm_campaign=364573&amp;referralcode=A314DFDBE96C354756A893C6E3E02493\">https://grafa.com/news/health-gh-research-shares-surge-as-depression-therapy-shows-strong-trial-results-364573</a></p>\n<p><a href=\"https://grafa.com/learn/shares-55513\">Shares</a> of <a href=\"https://grafa.com/company/gh-research-plc-13111\">GH Research </a><a href=\"https://grafa.com/asset/gh-research-plc-13111-ghrs.nasdaq\">(NASDAQ:GHRS)</a> skyrocketed 90% to $20.14 in premarket trading after the drug developer announced that its experimental therapy for treatment-resistant depression met its primary goal in a mid-stage clinical trial.</p>\n<p>The company reported that its therapy, GH001, significantly reduced the severity of depression as measured on a widely used clinical scale.</p>\n<p>Data from the trial showed that 57.5% of patients receiving GH001 experienced a reduction in disease severity within just eight days.</p>\n<p>In addition to hitting its main target, GH001 also met all secondary goals of the study, further strengthening its potential as a breakthrough treatment for patients who do not respond to conventional therapies.</p>\n<p>Meanwhile, <a href=\"https://grafa.com/company/gh-research-plc-13111\">GH Research </a>has seen strong momentum in its stock performance, with shares rising 20.7% in 2024.</p>\n<p>The latest trial success has fueled optimism among investors and the medical community, as the company advances GH001 toward further clinical development.</p></body></html>","text":"Full story: https://grafa.com/news/health-gh-research-shares-surge-as-depression-therapy-shows-strong-trial-results-364573 Shares of GH Research (NASDAQ:GHRS) skyrocketed 90% to $20.14 in premarket trading after the drug developer announced that its experimental therapy for treatment-resistant depression met its primary goal in a mid-stage clinical trial. The company reported that its therapy, GH001, significantly reduced the severity of depression as measured on a widely used clinical scale. Data from the trial showed that 57.5% of patients receiving GH001 experienced a reduction in disease severity within just eight days. In addition to hitting its main target, GH001 also met all secondary goals of the study, further strengthening its potential as a breakthrough treatment for patients who do not respond to conventional therapies. Meanwhile, GH Research has seen strong momentum in its stock performance, with shares rising 20.7% in 2024. The latest trial success has fueled optimism among investors and the medical community, as the company advances GH001 toward further clinical development.","highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/399633295237776","repostId":0,"isVote":1,"tweetType":1,"viewCount":79,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":957,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/399633295237776"}